Celyad Oncology to Announce First Half 2020 Financial Results and Host Conference Call
August 03, 2020 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy
July 14, 2020 01:00 ET
|
Celyad SA
Phase 1 clinical trial evaluating the off-the-shelf anti-BCMA CAR T candidate CYAD-211 for the treatment of relapsed/refractory multiple myeloma (r/r MM) expected to begin by year-end 2020CYAD-211...
Celyad Rebrands as Celyad Oncology
June 10, 2020 01:00 ET
|
Celyad SA
Shareholders approve new name which better reflects the Company’s ambition to pioneer CAR T cell therapies for cancer MONT-SAINT-GUIBERT, Belgium, June 10, 2020 (GLOBE NEWSWIRE) -- Celyad SA...
Celyad Provides Update on Allogeneic CAR-T Franchise including CYAD-101 and shRNA Platform at the 2020 ASCO Virtual Scientific Program
June 01, 2020 01:00 ET
|
Celyad SA
First-in-class TIM-based non-gene edited allogeneic CAR-T candidate, CYAD-101, shows encouraging clinical activity with no evidence of graft-versus-host disease in relapsed/refractory metastatic...
Celyad Announces June 2020 Conference Schedule
May 26, 2020 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 26, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Announces First Quarter 2020 Financial Results and Recent Business Highlights
May 07, 2020 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 07, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Appoints Seasoned Industry Executives to Board of Directors
May 06, 2020 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 06, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad to Present Update from CYAD-101 for Advanced Colorectal Cancer and Next-Generation shRNA Platform at 2020 ASCO Virtual Scientific Program
April 30, 2020 01:00 ET
|
Celyad SA
Two accepted abstracts will be presented virtually in a prerecorded poster presentation MONT-SAINT-GUIBERT, Belgium, April 30, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and...
Celyad to Host Remote 2020 Ordinary General Meeting
April 22, 2020 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, April 22, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Reports Full Year 2019 Financial Results and Provides Business Update
March 24, 2020 19:22 ET
|
Celyad SA
First patient successfully dosed in expansion cohort of autologous CYAD-01 THINK trial for patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes...